Literature DB >> 23329170

Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Nor Saadah M Azahri1, Mary M Kavurma.   

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has dual functions mediating both apoptosis and survival of cells. This review focusses on the current regulatory factors that control TRAIL transcription. Here, we also highlight the role of distinct transcription factors that co-operate and regulate TRAIL in different pathological states. A better understanding of the molecular signalling pathways of TRAIL-induced cell death and survival in disease may lead to more sophisticated technologies for novel therapeutic targets.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23329170     DOI： 10.1007/s00018-013-1264-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  100 in total

1.  Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes.

Authors:  Cinzia Fionda; Filomena Nappi; Mario Piccoli; Luigi Frati; Angela Santoni; Marco Cippitelli
Journal:  Mol Pharmacol       Date:  2007-08-02       Impact factor: 4.436

2.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

Authors:  C S Mitsiades; S P Treon; N Mitsiades; Y Shima; P Richardson; R Schlossman; T Hideshima; K C Anderson
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

3.  Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage.

Authors:  S M Mariani; P H Krammer
Journal:  Eur J Immunol       Date:  1998-03       Impact factor: 5.532

4.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

5.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

6.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

7.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

Authors:  Edith M Janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas S Griffith; Douglas R Green; Stephen P Schoenberger
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

Review 8.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

9.  TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death.

Authors:  Kageaki Kuribayashi; Gabriel Krigsfeld; Wenge Wang; Jing Xu; Patrick A Mayes; David T Dicker; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2008-12       Impact factor: 4.742

Review 10.  Following TRAIL's path in the immune system.

Authors:  Christina Falschlehner; Uta Schaefer; Henning Walczak
Journal:  Immunology       Date:  2009-06       Impact factor: 7.397
View more
  8 in total

1.  Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.

Authors:  Paloma S Souza; James P Madigan; Jean-Pierre Gillet; Khyati Kapoor; Suresh V Ambudkar; Raquel C Maia; Michael M Gottesman; King Leung Fung
Journal:  Exp Cell Res       Date:  2015-06-19       Impact factor: 3.905

2.  Partial Protection of PC12 Cells from Cellular Stress by Low-Dose Sodium Nitroprusside Pre-treatment.

Authors:  Judit Varga; Judit Bátor; Gergő Nádasdi; Zita Árvai; Renáta Schipp; József Szeberényi
Journal:  Cell Mol Neurobiol       Date:  2015-12-01       Impact factor: 5.046

3.  Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.

Authors:  Siân P Cartland; Hanis H Harith; Scott W Genner; Lei Dang; Victoria C Cogger; Melissa Vellozzi; Belinda A Di Bartolo; Shane R Thomas; Leon A Adams; Mary M Kavurma
Journal:  Sci Rep       Date:  2017-05-15       Impact factor: 4.379

4.  TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.

Authors:  Belinda A Di Bartolo; Siân P Cartland; Hanis H Harith; Yuri V Bobryshev; Michael Schoppet; Mary M Kavurma
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

5.  TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- mice.

Authors:  Siân P Cartland; Jonathan H Erlich; Mary M Kavurma
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

6.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms.

Authors:  Belinda Ann Di Bartolo; Siân Peta Cartland; Leonel Prado-Lourenco; Thomas Scott Griffith; Carmine Gentile; Jayant Ravindran; Nor Saadah Muhammad Azahri; Thuan Thai; Amanda Wing Shee Yeung; Shane Ross Thomas; Mary Meltem Kavurma
Journal:  J Am Heart Assoc       Date:  2015-11-16       Impact factor: 5.501

Review 7.  TRAIL signals, extracellular matrix and vessel remodelling.

Authors:  Manisha S Patil; Siân P Cartland; Mary M Kavurma
Journal:  Vasc Biol       Date:  2020-06-15

8.  Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.

Authors:  Tatsushi Yoshida; Kenta Yamasaki; Kenjiro Tadagaki; Yasumichi Kuwahara; Akifumi Matsumoto; Adèm Ejub Sofovic; Noriko Kondo; Toshiyuki Sakai; Tsukasa Okuda
Journal:  Int J Oncol       Date:  2021-12-27       Impact factor: 5.650
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.